Skip to main content

Table 4 Percentage of positive CD31 staining in tumor section

From: A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity

Group % of CD31 in Colo-205 % of CD31 in A549
PBS 6.2 (+/- 2.1) 7.1 (+/-3.2)
Doxorubicin, 3 mg/kg 6.8 (+/- 3.6) not done
HB-002.1, 5 mg/kg 1.9 (+/- 0.9) 0.7 (+/- 0.2)
Bevacizumab, 20 mg/kg not done 3.9 (+/- 2.9)
  1. Note: Average (+/- SEM) from 3 samples in each group is shown.
\